Cultured Hematopoietic Stem Cells and Method for Expansion and Analysis Thereof
AssigneeWhitehead Institute for Biomedical Research
InventorsChengCheng Zhang, Harvey Lodish
Life of this patent
Estimating the term…
Abstract
Hematopoietic stem cells and methods for ex vivo expansion of hematopoietic stem cells are provided. The methods comprise culturing the cells in a media containing an effective amount insulin-like growth factor (IGF), fibroblast growth factor (FGF), thrombopoietin (TPO), and stem cell factor (SCF), under conditions sufficient for expansion of said cells. Methods for identifying expanded hematopoeitic stem cells and kits for ex vivo expansion of hematopoietic stem cells are also provided.
Claims27
1-22. (canceled)
A method for identifying hematopoietic stem cells, comprising characterizing surface phenotype of cultured cells, wherein a surface phenotype of Sca+, IGF-2 receptor+, CD31+ and one or more of the group consisting of PrP−, Tie-2−, CD62L−, prominin 1− (AC133−), CD34−, CD38−, and Lin− is indicative of a hematopoietic stem cell.
Cultured hematopoietic stem cells having a surface phenotype of Sca+, IGF-2 receptor+, CD31+ and one or more of PrP−, Tie-2−, CD62L−, prominin 1− (AC133−), CD34−, CD38−, and Lin−.
A kit for expanding hematopoietic stem cells ex vivo comprising
- a) insulin-like growth factor-2 (IGF-2) and at least one factor selected from group consisting of SCF, TOP, and FGF-1;
- and
- b) instructions for expanding hematopoietic stem cells ex vivo.
A hematopoietic stem cell from a population of ex vivo cultured hematopoietic stem cells, having a surface phenotype of Sca+, IGF-2 receptor+, CD31+ and one or more of the group consisting of PrP−, Tie-2−, CD62L−, prominin 1− (AC133−), CD34−, CD38−, and Lin−.
Dependencies are inferred from the claim text.